Antihypertensive effect of the new oral angiotensin converting enzyme inhibitor "MK-421".

Détails

ID Serval
serval:BIB_E585E8F98667
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Antihypertensive effect of the new oral angiotensin converting enzyme inhibitor "MK-421".
Périodique
Lancet
Auteur(s)
Gavras H., Biollaz J., Waeber B., Brunner H.R., Gavras I., Davies R.O.
ISSN
0140-6736
Statut éditorial
Publié
Date de publication
1981
Peer-reviewed
Oui
Volume
2
Numéro
8246
Pages
543-547
Langue
anglais
Résumé
The effects of the new oral converting enzyme inhibitor "MK-421" on blood pressure, plasma renin activity, plasma angiotensin II, aldosterone, and angiotensin converting enzyme were assessed in 16 hypertensive patients. Maximum (maintenance) doses ranged from 2.5 mg-40 mg daily. Blood pressure decreased from 177 +/- 7/111 +/- 4 mm Hg to 145 +/- 6/94 +/- 3 mm Hg supine and from 174 +/- 7/177 +/- 4 mm Hg to 142 +/- 6/101 +/- 3 mm Hg upright (mean +/- SEM, p less than 0.001 for both). Heart rate did not change significantly. Plasma renin activity rose during treatment, whereas plasma angiotensin II, aldosterone, and angiotensin converting enzyme remained suppressed at 24h after the maximum dose. Magnitude of blood pressure reduction after the maximum dose did not correlate with baseline plasma renin activity levels. No side-effects were noted during the 2-10 week observation period. MK-421 is similar to its predecessors in efficacy and clinical and biochemical correlates, the main difference being its higher potency and longer duration of action.
Mots-clé
Administration, Oral, Adult, Aged, Aldosterone, Angiotensin II, Angiotensin-Converting Enzyme Inhibitors, Blood Pressure, Dipeptides, Double-Blind Method, Drug Evaluation, Enalapril, Female, Humans, Hypertension, Male, Middle Aged, Renin
Pubmed
Web of science
Création de la notice
25/01/2008 11:41
Dernière modification de la notice
03/03/2018 22:15
Données d'usage